Company Overview
About Neuron23
Neuron23 is a clinical-stage biotechnology company developing precision medicines for genetically defined neurological and immunological diseases. The company combines advances in human genetics with AI-based drug discovery and biomarker platforms to identify novel molecular targets and advance therapies for conditions with high unmet medical need. Its lead program, NEU-411, is a brain-penetrant, potent, and selective LRRK2 inhibitor targeting early Parkinson's disease.
Business Model & Competitive Advantage
In 2025, Neuron23 announced a $96.5M Series D financing round led by a major healthcare investor, with participation from Westlake Village BioPartners, SoftBank Vision Fund 2, Redmile Group, Blue Owl, Kleiner Perkins, HBM Healthcare Investments, and Acorn Bioventures. Alongside this raise, the company dosed the first patient in its global Phase 2 NEULARK clinical trial of NEU-411, with topline data expected in 2027. The company also initiated Phase 1 dosing of NEU-111, a TYK2 inhibitor targeting immunological diseases, in December 2024.
Competitive Landscape 2025–2026
Neuron23's AI-powered approach to drug discovery—using machine learning to map genetic underpinnings of neurodegeneration—positions it at the frontier of precision medicine. Its focus on genetically validated targets with measurable biomarkers reduces de-risking timelines compared to traditional approaches, making it a compelling example of how computational biology is transforming the drug development pipeline.
Key Differentiators
Strong Challenger
Neuron23 is an established challenger with significant market presence and competitive offerings in Life Sciences & BioTech.
Frequently Asked Questions
Similar Brands
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Compare Neuron23 with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Neuron23? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Neuron23 Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Neuron23 vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →